Article

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastoma

2026-05-11

Abstract excerpt

<h4>ABSTRACT</h4> Glioblastoma (GBM) is an aggressive primary brain tumor associated with a median survival of approximately 15 months following diagnosis. Current standard-of-care treatment includes surgical resection followed by radiotherapy and chemotherapy with the DNA-alkylating agent temozolomide (TMZ). However, tumor recurrence in a therapy-resistant state remains a major driver of poor patient outcomes. T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2734d6dc-cae3-579c-b563-a89263809bee
DOI: 10.64898/2026.05.07.723296

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaDOI 10.64898/2026.05.07.723296Read

Functional Genomic Screens Reveal RBBP4 as a Key Regulator of Cell Cycle Progression in TMZ-Resistant GlioblastomaSemantic proximity Read

Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cellsSemantic proximity Read

DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivoSemantic proximity Read

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read

Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in GlioblastomaSemantic proximity Read

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Semantic proximity Read

Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide-Resistant Glioblastoma.Semantic proximity Read

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastomaSemantic proximity Read

Identification of inter- and intra-tumoral molecular phenotypes steering temozolomide resistance in patient-derived glioblastoma cellsSemantic proximity Read